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Clinical Pharmacology: Advances and Applications is now in its second year. The 
turnaround time for the publishing of manuscripts is a few weeks. Peer reviews are 
high quality, and the journal is open access, filling an important niche in academic 
medical publishing.
Specifically, the journal was designed to bridge the gap between basic science and 
clinical practice. Because of the explosion in the market of new drugs and biomarkers 
secondary to in silico drug design, high-throughput screens, large cooperative group 
clinical trials, and patient characterizations by genomic and proteomic analyses, we 
now have a huge amount of information on drug targets and host responses. Although 
such a plethora of knowledge should promise rapid advances, in fact in many cases 
it has led to a partial paralysis of action both by pharmacologists and by physicians. 
How do we make sense of this massive complexity? Will any action we take be seen 
as erroneous in weeks or months?
Because we have welcomed submissions on all fields of the pharmacology of human 
disease and treatment (from diabetes to seizure disorders and from the side effects of 
drugs to predictive biomarkers), the journal has made a special effort to publish rapidly 
a range of articles that use language that will engage a broad audience and clarify 
the pharmacodynamics and physiology of compounds. The editors believe that cross-
fertilization between different fields will accelerate medical advances. The articles in 
Clinical Pharmacology: Advances and Applications vary from small patient series or 
case reports to larger clinical trials. The common theme is an effort to connect drug 
chemistry and biology with clinical effects.
In the coming year, with the help of Dove Medical Press, we hope to gain entry 
into larger science and medical literature search engines.1 We will continue to focus on 
studies that improve our understanding of medications in order to reduce side effects, 
improve response rates, and lead to better drug design. We anticipate better commu-
nication between research pharmacologists and clinical investigators and will seek 
to introduce “Letters to the Editor”, beginning next year. As our readership expands 
along with the breadth and depth of work in this area, please do not hesistate to contact 
me at any time to suggest improvements to Clinical Pharmacology: Advances and 
Applications and to help us grow the reputation of our journal.
Notes: 1Clinical Pharmacology: Advances and Applications is eligible for online indexing in late 2010.